Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer

• Status: Active, not recruiting
• Trial end date: 2022-04-30

Summary

The dynamics of immune systems by Olaparib and its changes by combination with immune-oncology agents will be uncovered.

The combination of Olaparib with Durvalumab with paclitaxel is tolerable and efficacious in gastric cancer.

Primary Objectives:

To assess the effect of Durvalumab in combination with olaparib and paclitaxel on DCR (Disease control rate) in gastric cancer patients

-Disease control rate (based on RECIST v1.1)

Secondary Objective(s):

• Efficacy: overall response rate (RECIST 1.1, ir response), progression-free survival, duration of response, overall survival, overall survival at 6 month, overall survival at 1 year, EORTC QLQ-C30,

• Safety: toxicity (CTCAE V4.1), irAE Phase: Phase 2

Details

• Lead Sponsor: Do-Youn Oh
• Collaborator: AstraZeneca
• Treatments: Albumin-Bound Paclitaxel; Antibodies, Monoclonal; Durvalumab; Olaparib; Paclitaxel